PET-FDG Imaging in Metastatic Breast Cancer Treated with High Dose Chemotherapy and Stem Cell Support
Abstract
This study is designed to assess the effectiveness of positron emission tomography (PET) with fluorodeoxyglucose in patients with metastatic breast cancer undergoing high dose chemotherapy with stem cell rescue. It includes patients enrolled on two high dose chemotherapy trials (PBT-1 and UCPP # 3195). So far, 31 patients have been enrolled in the protocol, and the study is proceeding as planned. We have performed a preliminary analysis of the PET studies of 24 patients performed before high dose chemotherapy. In this subgroup of patients, 17 had active disease demonstrated on the PET study, and 7 had no evidence of metabolically active disease. Two subjects had disease involvement demonstrated only on PET imaging and proven at pathology or follow-up. Several repeat studies have been performed and will he analyzed when enough prognostic information becomes available. Patient accrual is ongoing and the study is proceeding as scheduled. PET FDG imaging is a promising tool that can potentially predict early therapeutic failure.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 1998
- Accession Number
- ADA368392
Entities
People
- Abass Alavi
Organizations
- University of Pennsylvania